Literature DB >> 3762862

Antisera to vasoactive intestinal polypeptide inhibit basal prolactin release from dispersed anterior pituitary cells.

T C Hagen, M A Arnaout, W J Scherzer, D R Martinson, T L Garthwaite.   

Abstract

Vasoactive intestinal polypeptide (VIP) has been identified in hypothalamic tissue, is secreted into hypophysial portal blood, and stimulates prolactin (PRL) release in vivo and in vitro. It has been proposed, therefore, that VIP is a physiologic PRL-releasing factor. In this study, we confirm that VIP stimulates PRL release from rat pituitary cells in vitro, and demonstrate that an anti-VIP antiserum blocks VIP-induced PRL secretion. Surprisingly, the anti-VIP antiserum inhibited basal PRL secretion from rat pituitary cells in 3 separate experiments. Data from these experiments were pooled, as the responses were similar, revealing basal PRL release of 10.7 +/- 1.3 ng rPRL/10(5) cells (X +/- SE), while anti-VIP antisera significantly inhibited release to 4.4 +/- 0.6 ng rPRL/10(5) cells (p less than 0.001). PRL release in incubates containing control non-immune sera did not differ from basal release, 8.1 ng rPRL/10(5) cells. A further control experiment was conducted wherein cells were incubated with an anti-ACTH antiserum, representing another hyperimmune serum, which had no effect on PRL secretion. These data suggest that VIP, in addition to its possible role as a hypothalamic-derived PRL-releasing factor, may play a role within the pituitary as a regulator of basal PRL secretion.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3762862     DOI: 10.1159/000124594

Source DB:  PubMed          Journal:  Neuroendocrinology        ISSN: 0028-3835            Impact factor:   4.914


  9 in total

1.  Different ultrastructural localization of VIP and prolactin in anterior pituitary cells of rats chronically treated with estrogen.

Authors:  K Köves; I L Chen; T J Görcs; J G Scammell; A Arimura
Journal:  Endocrine       Date:  1996-10       Impact factor: 3.633

Review 2.  Paracrinicity: the story of 30 years of cellular pituitary crosstalk.

Authors:  C Denef
Journal:  J Neuroendocrinol       Date:  2008-01       Impact factor: 3.627

Review 3.  Ontogenic studies of the neural control of adenohypophyseal hormones in the rat. II. Prolactin.

Authors:  D Becú-Villalobos; I M Lacau-Mengido; G S Díaz-Torga; C Libertun
Journal:  Cell Mol Neurobiol       Date:  1992-02       Impact factor: 5.046

Review 4.  Towards a functional significance of peptides and biogenic amines produced by the anterior pituitary.

Authors:  H Houben; D Tilemans; C Denef
Journal:  J Endocrinol Invest       Date:  1990-11       Impact factor: 4.256

5.  Vasoactive intestinal peptide in the human pituitary gland and adenomas. An immunocytochemical study.

Authors:  D W Hsu; P N Riskind; E T Hedley-Whyte
Journal:  Am J Pathol       Date:  1989-08       Impact factor: 4.307

6.  Effect of concomitant progesterone administration or the effect of removal of estrogen capsule on changes caused by long-term estrogen treatment in pituitary VIP immunoreactivities.

Authors:  Andrea Heinzlmann; Katalin Köves; György M Nagy
Journal:  Endocrine       Date:  2010-03-30       Impact factor: 3.633

7.  Estrogen attenuates expression of calcitonin-like immunoreactivity in the anterior pituitary gland.

Authors:  Z Li; G V Shah
Journal:  Endocrine       Date:  1995-06       Impact factor: 3.633

8.  Neonatal androgenization increases vasoactive intestinal peptide levels in rat anterior pituitary: possible involvement of vasoactive intestinal peptide in the neonatal androgenization-induced hyperprolactinemia.

Authors:  H Watanobe; S Sasaki; K Takebe
Journal:  J Endocrinol Invest       Date:  1991-11       Impact factor: 4.256

9.  Hedgehog signaling in endocrine and folliculo-stellate cells of the adult pituitary.

Authors:  Dominik Simon Botermann; Nadine Brandes; Anke Frommhold; Ina Heß; Alexander Wolff; Arne Zibat; Heidi Hahn; Rolf Buslei; Anja Uhmann
Journal:  J Endocrinol       Date:  2021-03       Impact factor: 4.286

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.